For patients 12 years of age and older living with anti-AChR or anti-MuSK antibody-positive **generalized myasthenia gravis (gMG)**

With IMAAVY™ disease control can last and last and last

as measured by improvement in daily function* in a 24-week clinical study

AChR=acetylcholine receptor; MuSK=muscle-specific tyrosine kinase.

*Measured using the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, which assesses the impact of gMG on 8 daily-function items that are typically affected in gMG. The average reduction from baseline to Weeks 22, 23, and 24 in MG-ADL total score was 4.7 for people taking IMAAVY™ + current gMG treatment and 3.3 for people taking placebo + current gMG treatment.

imaavy™
(nipocalimab-aahu)

WHAT IS IMAAVY™ (nipocalimab-aahu)?

IMAAVY™ is a prescription medicine used to treat adults and children 12 years of age and older with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

It is not known if IMAAVY™ is safe and effective in children under 12 years of age.

SELECTED IMPORTANT SAFETY INFORMATION

IMAAVY™ is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to IMAAVY™. Reactions have included angioedema and anaphylaxis. IMAAVY™ is a prescription medicine that may cause serious side effects, including infections, allergic (hypersensitivity) reactions, and infusion-related reactions. People treated with IMAAVY™ should not receive live vaccines. Please read the Important Safety Information on pages 10–11 and the Medication Guide for IMAAVY™ to learn more about these and other risks associated with IMAAVY™. Discuss any questions you have with your healthcare provider.

Could IMAAVY™ be the right treatment for you?

If you are looking for a treatment option for gMG that can help improve daily function and muscle weakness, consider IMAAVY™.

In a clinical study, IMAAVY™ helped adults with antibody-positive* gMG achieve significant improvement in daily function,† as well as improvement in muscle weakness.‡

Ask your doctor about IMAAVY™

Individual results may vary. Talk to your healthcare provider to see if IMAAVY™ is right for you.

*This study included adult patients with anti-AChR or anti-MuSK antibody-positive gMG.

†Measured using the MG-ADL scale, which assesses the impact of gMG on 8 daily-function items that are typically affected in gMG. The average reduction from baseline to Weeks 22, 23, and 24 in MG-ADL total score was 4.7 for people taking IMAAVY™ + current gMG treatment and 3.3 for people taking placebo + current gMG treatment.

‡Measured using the Quantitative Myasthenia Gravis (QMG) scale, which assesses muscle weakness based on 13 items. The average reduction from baseline to Weeks 22 and 24 in QMG score was 4.9 for people taking IMAAVY™ + current gMG treatment and 2.1 for people taking placebo + current gMG treatment.

SELECTED IMPORTANT SAFETY INFORMATION

IMAAVY™ is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to IMAAVY™. Reactions have included angioedema and anaphylaxis. IMAAVY™ is a prescription medicine that may cause serious side effects, including infections, allergic (hypersensitivity) reactions, and infusion-related reactions. People treated with IMAAVY™ should not receive live vaccines. Please read the Important Safety Information on pages 10–11 and the Medication Guide for IMAAVY™ to learn more about these and other risks associated with IMAAVY™. Discuss any questions you have with your healthcare provider.

imaavy™ (nipocalimab-aahu)

A 24-week clinical study explored the effectiveness and safety of IMAAVY™ in adult patients living with antibody-positive gMG*

Significant improvement in daily function

4+ average point reduction in MG-ADL†

- Patients taking IMAAVY™ + current gMG treatment§ experienced a 4.7-point improvement in MG-ADL on average
- Patients taking placebo + current gMG treatment§ experienced a 3.3-point improvement on average
- This was measured using results averaged from Weeks 22, 23, and 24 of the study compared to baseline

Significant improvement in muscle weakness

4+ average point reduction in QMG‡

- Patients taking IMAAVY™ + current gMG treatment§ experienced a 4.9-point improvement in QMG on average
- Patients taking placebo + current gMG treatment§ experienced a 2.1-point improvement on average
- This was measured using results averaged from Weeks 22 and 24 of the study compared to baseline

Individual results may vary. Talk to your healthcare provider to see if IMAAVY™ is right for you.

*This study included adult patients with anti-AChR or anti-MuSK antibody-positive gMG.

†The MG-ADL scale assesses the impact of gMG on 8 daily-function items that are typically affected in gMG.

‡The QMG scale assesses muscle weakness based on 13 items.

§In the study, patients were given IMAAVY™ + their current gMG treatment or placebo + their current gMG treatment. Current therapies included acetylcholinesterase inhibitors, steroids, or non-steroidal immunosuppressive therapies, taken together or separately.

SELECTED IMPORTANT SAFETY INFORMATION

IMAAVY™ is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to IMAAVY™. Reactions have included angioedema and anaphylaxis. IMAAVY™ is a prescription medicine that may cause serious side effects, including infections, allergic (hypersensitivity) reactions, and infusion-related reactions. People treated with IMAAVY™ should not receive live vaccines. Please read the Important Safety Information on pages 10–11 and the Medication Guide for IMAAVY™ to learn more about these and other risks associated with IMAAVY™. Discuss any questions you have with your healthcare provider.

imaavy™ (nipocalimab-aahu)

What are the possible side effects of IMAAVY™?

The most common side effects in people with gMG treated with IMAAVY™ include:

- infection in parts of your body that you use for breathing (respiratory tract infection)
- swelling in your hands, ankles, or feet (peripheral edema)
- muscle spasms

IMAAVY™ may cause serious side effects, including:

- **Infections.** Infections are a common side effect of IMAAVY™ that can be serious. Receiving IMAAVY™ may increase your risk of infection. Tell your healthcare provider right away if you have any of the following symptoms of infection:
  - fever
  - chills
  - shivering
  - cough
  - sore throat
  - fever blisters
  - burning when you urinate
- **Allergic (hypersensitivity) reactions.** Allergic reactions may happen during or up to a few weeks after your IMAAVY™ infusion. Get emergency medical help right away if you get any of these symptoms during or after your IMAAVY™ infusion, which may be part of a serious allergic reaction:
  - swelling of your face, lips, mouth, tongue, or throat
  - difficulty swallowing or breathing
  - itchy rash (hives)
  - chest pain or tightness
- **Infusion-related reactions.** Tell your healthcare provider right away if you get any of the following symptoms during or a few days after your infusion of IMAAVY™:
  - headache
  - rash
  - nausea
  - fatigue
  - dizziness
  - chills
  - flu-like symptoms
  - redness of skin

These are not all of the possible side effects of IMAAVY™. If you have a reaction during your IMAAVY™ infusion, your healthcare provider may decide to give IMAAVY™ more slowly or to stop your infusion.

Call your healthcare provider for medical advice about side effects.
You may report side effects to FDA at 1-800-FDA-1088.

Please see the Important Safety Information on pages 10–11 and the Medication Guide for IMAAVY™. Discuss any questions you have with your healthcare provider.

imaavy™ (nipocalimab-aahu)

HOW IMAAVY™ WORKS

IMAAVY™ is designed to reduce harmful IgG antibodies, including anti-AChR and anti-MuSK, by binding and blocking FcRn receptors

Neonatal fragment crystallizable receptor (FcRn) is a protein that can keep harmful IgG antibodies in your body longer.

This allows the harmful IgG antibodies to continue to attach to muscle receptors and interfere with the signals sent from nerves.

IMAAVY™ belongs to the FcRn blocker class of treatments.

Because IMAAVY™ binds and blocks FcRn receptors, harmful IgG antibodies, including anti-AChR and anti-MuSK, are reduced.

These antibodies can cause gMG symptoms.



Data rates may apply.

Scan or click here to see how IMAAVY™ works.

SELECTED IMPORTANT SAFETY INFORMATION

IMAAVY™ is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to IMAAVY™. Reactions have included angioedema and anaphylaxis. IMAAVY™ is a prescription medicine that may cause serious side effects, including infections, allergic (hypersensitivity) reactions, and infusion-related reactions. People treated with IMAAVY™ should not receive live vaccines. Please read the Important Safety Information on pages 10–11 and the Medication Guide for IMAAVY™ to learn more about these and other risks associated with IMAAVY™. Discuss any questions you have with your healthcare provider.

imaavy™ (nipocalimab-aahu)

IMAAVY™ can help you manage gMG symptoms on a schedule you can plan around

How IMAAVY™ is taken

IMAAVY™ is given by a healthcare professional as an intravenous (IV) infusion

At your first appointment, your healthcare provider will give you a starting dose of IMAAVY™ as an IV infusion lasting at least **30 minutes**. An IV infusion is given through a needle placed into your vein.*

Two weeks later you will receive your next dose of IMAAVY™ infusion lasting at least **15 minutes**. Your following doses will be given every **2 weeks**.

After each dose, your healthcare provider will **monitor you for 30 minutes** to look for any signs or symptoms of an infusion-related or hypersensitivity reaction.

Allergic reactions can happen during your IMAAVY™ infusion. Tell your healthcare provider right away if you get any of these symptoms during your IMAAVY™ infusion.

*If you have a reaction during your IMAAVY™ infusion, your healthcare provider may decide to administer IMAAVY™ more slowly or stop your infusion. If you miss a scheduled IMAAVY™ infusion, you should receive your next dose as soon possible.

SELECTED IMPORTANT SAFETY INFORMATION

IMAAVY™ is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to IMAAVY™. Reactions have included angioedema and anaphylaxis. IMAAVY™ is a prescription medicine that may cause serious side effects, including infections, allergic (hypersensitivity) reactions, and infusion-related reactions. People treated with IMAAVY™ should not receive live vaccines. Please read the Important Safety Information on pages 10–11 and the Medication Guide for IMAAVY™ to learn more about these and other risks associated with IMAAVY™. Discuss any questions you have with your healthcare provider.

imaavy™ (nipocalimab-aahu)

Where can you receive IMAAVY™ infusions?

Your healthcare provider may administer IMAAVY™ in their office.

An infusion service provider may be able to coordinate **at-home administration** of IMAAVY™.

Some hospitals offer IMAAVY™ as an outpatient service.

You can receive IMAAVY™ at an **infusion center** that carries it.

Data rates may apply.

Scan or click here to locate an infusion center that may carry IMAAVY™.

SELECTED IMPORTANT SAFETY INFORMATION

IMAAVY™ is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to IMAAVY™. Reactions have included angioedema and anaphylaxis. IMAAVY™ is a prescription medicine that may cause serious side effects, including infections, allergic (hypersensitivity) reactions, and infusion-related reactions. People treated with IMAAVY™ should not receive live vaccines. Please read the Important Safety Information on pages 10–11 and the Medication Guide for IMAAVY™ to learn more about these and other risks associated with IMAAVY™. Discuss any questions you have with your healthcare provider.

imaavy™ (nipocalimab-aahu)

imaavy withMe

For eligible patients using commercial insurance

IMAAVY withMe Savings Program

Pay as little as $0 per infusion

Program consists of **Medicine Cost Support** for the cost of IMAAVY™ medicine and **Treatment Administration Cost Support** for certain IMAAVY™ infusion administration and related monitoring costs. Maximum program benefit per calendar year shall apply. Offer subject to change or end without notice. Restrictions, including monthly maximums, may apply. See program requirements at **IMAAVYwithMeSavings.com**.

Please see the Important Safety Information on pages 10–11 and the Medication Guide for IMAAVY™. Discuss any questions you have with your healthcare provider.

imaavy™ (nipocalimab-aahu)

Once you and your healthcare provider have decided that IMAAVY™ is right for you

Get personalized support tailored to your unique needs with **IMAAVY withMe**

Sign up and get access to:

Access and cost support

We'll explore a range of options that can help you access and afford your IMAAVY™ treatment

Resources tailored to your needs

Get helpful tips, tools, and access to the Patient Portal for account and insurance coverage details

A dedicated Nurse Navigator*

A rare-disease–trained nurse will partner with you to prepare for infusions, answer questions, and help manage treatment challenges

The support and resources provided by IMAAVY withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

*Nurse Navigators do not provide medical advice. Please ask your doctor any questions you might have about your disease and treatment.

Data rates may apply.

Scan or click here to sign up for patient support offered by **IMAAVY withMe**

Please see the Important Safety Information on pages 10–11 and the Medication Guide for IMAAVY™. Discuss any questions you have with your healthcare provider.

imaavy™ (nipocalimab-aahu)

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about IMAAVY™?

IMAAVY™ is a prescription medicine that may cause serious side effects, including:

- **Infections** are a common side effect of IMAAVY™ that can be serious. Receiving IMAAVY™ may increase your risk of infection. Tell your healthcare provider right away if you have any of the following infection symptoms:
  - fever
  - chills
  - shivering
  - cough
  - sore throat
  - fever blisters
  - burning when you urinate
- **Allergic (hypersensitivity) reactions** may happen during or up to a few weeks after your IMAAVY™ infusion. Get emergency medical help right away if you get any of these symptoms during or after your IMAAVY™ infusion:
  - a swollen face, lips, mouth, tongue, or throat
  - difficulty swallowing or breathing
  - itchy rash (hives)
  - chest pain or tightness
- **Infusion-related reactions** are possible. Tell your healthcare provider right away if you get any of these symptoms during or a few days after your IMAAVY™ infusion:
  - headache
  - rash
  - nausea
  - fatigue
  - dizziness
  - chills
  - flu-like symptoms
  - redness of skin

Do not receive IMAAVY™ if you have a severe allergic reaction to nipocalimab-aahu or any of the ingredients in IMAAVY™. Reactions have included angioedema and anaphylaxis.

Before using IMAAVY™, tell your healthcare provider about all of your medical conditions, including if you:

- ever had an allergic reaction to IMAAVY™.
- have or had any recent infections or symptoms of infection.
- have recently received or are scheduled to receive an immunization (vaccine). People who take IMAAVY™ should not receive live vaccines.
- are pregnant, plan to become pregnant, or are breastfeeding. It is not known whether IMAAVY™ will harm your baby.

  Pregnancy Safety Study. There is a pregnancy safety study for IMAAVY™ if IMAAVY™ is given during pregnancy or you become pregnant while receiving IMAAVY™. Your healthcare provider should report IMAAVY™ exposure by contacting Janssen at 1-800-526-7736 or www.IMAAVY.com.

imaavy™ (nipocalimab-aahu)

IMPORTANT SAFETY INFORMATION (cont)

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of IMAAVY™?

IMAAVY™ may cause serious side effects. See "What is the most important information I should know about IMAAVY™?"

The most common side effects of IMAAVY™ include: respiratory tract infection, peripheral edema (swelling in your hands, ankles, or feet), and muscle spasms.

These are not all the possible side effects of IMAAVY™. Call your doctor for medical advice about side effects. **You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.**

Please see the full Prescribing Information and Medication Guide for IMAAVY™ and discuss any questions you have with your doctor.

Dosage Form and Strengths: IMAAVY™ is supplied as a 300 mg/1.62 mL and a 1,200 mg/6.5 mL (185 mg/mL) single-dose vial per carton for intravenous injection.

cp-509746v1

imaavy™ (nipocalimab-aahu)

MAKE THE MOST OF YOUR VISIT

Asking the right questions can help you and your healthcare provider find a gMG treatment that's right for you

Your healthcare provider is here to help. Here are some questions to help guide you during your discussion.

Since your last visit, which gMG symptoms have been bothering you the most?

How do you feel about the current control of your gMG symptoms?

Have more questions? Print this page and use this space to write them down.

Please see the Important Safety Information on pages 10–11 and the Medication Guide for IMAAVY™. Discuss any questions you have with your healthcare provider.

imaavy™ (nipocalimab-aahu)

Treatment goals:

Consider tracking your symptoms with a mobile app, like the "MyMG" app from the Myasthenia Gravis Foundation of America (MGFA).

Scan the QR code or click here to track your symptoms with the MyMG app.

Data rates may apply.

Please see the Important Safety Information on pages 10–11 and the Medication Guide for IMAAVY™. Discuss any questions you have with your healthcare provider.

imaavy™ (nipocalimab-aahu)

Discover what IMAAVY™ could do for you

Significant improvement

in daily function* and muscle weakness†

Disease control that lasts,

as measured by improvement in daily function* in a 24-week clinical study

Talk to your healthcare provider about IMAAVY™

Scan or click here to visit IMAAVY.com to learn more

Data rates may apply.

*Measured using the MG-ADL scale, which assesses the impact of gMG on 8 daily-function items that are typically affected in gMG. The average reduction from baseline to Weeks 22, 23, and 24 in MG-ADL total score was 4.7 for people taking IMAAVY™ + current gMG treatment and 3.3 for people taking placebo + current gMG treatment.

†Measured using the QMG scale, which assesses muscle weakness based on 13 items. The average reduction from baseline to Weeks 22 and 24 in QMG score was 4.9 for people taking IMAAVY™ + current gMG treatment and 2.1 for people taking placebo + current gMG treatment.

SELECTED IMPORTANT SAFETY INFORMATION

IMAAVY™ is not for everyone; only your healthcare provider can decide if it's right for you. Do not use if you are allergic to IMAAVY™. Reactions have included angioedema and anaphylaxis. IMAAVY™ is a prescription medicine that may cause serious side effects, including infections, allergic (hypersensitivity) reactions, and infusion-related reactions. People treated with IMAAVY™ should not receive live vaccines. Please read the Important Safety Information on pages 10–11 and the Medication Guide for IMAAVY™ to learn more about these and other risks associated with IMAAVY™. Discuss any questions you have with your healthcare provider.

05/25 cp-507135v1

Johnson&Johnson

imaavy™ (nipocalimab-aahu)